Treatment Patterns and Clinical Outcomes in High-Risk Newly Diagnosed Multiple Myeloma Patients Carrying the 17p Deletion.
This retrospective study reports outcomes among multiple myeloma patients harboring the high-risk del17p mutation. Among the 60 patients enrolled, the overall response rate after induction was 85%. Median overall survival was 43 months. Autologous stem cell transplant was associated with improved overall survival (median, 59.7 vs 28.7 months). Despite currently available treatment modalities, multiple melanoma […]
